PI-RADS 2.1 on biparametric MRI matches international benchmarks for prostate cancer detection in Irish cohort

Retrospective single-center study (n=328) finds bpMRI + PI-RADS 2.1 achieves 92% sensitivity and 49% specificity for clinically significant prostate cancer (Gleason ≥7), with cancer detection rates of 31%, 54%, and 96% for PI-RADS 3, 4, and 5 — consistent with international data.

• Retrospective review of 328 consecutive patients undergoing pre-biopsy prostate MRI and biopsy at a single Irish tertiary center in 2023; 182 (55%) had clinically significant prostate cancer (Gleason score ≥7).
• 92% of clinically significant cancers scored PI-RADS ≥3; sensitivity 92%, specificity 49% — no 95% CIs or p-values reported in source.
• Key limitation: single-center, retrospective design at one Irish tertiary referral center limits generalizability; no comparison with full multiparametric MRI (mpMRI) performance.

RadPigeon summaries are original and for information only. They are not clinical advice.